TX-1918

• UNSPSC Description:

  TX-1918 is an inhibitor for eukaryotic elongation factor 2 kinase (eEF2-K) and Src kinase with IC50 of 0.44 and 4.4 μM, respectively. TX-1918 exhibits cytotoxicity in cell HepG2 and HCT116, with IC50 of 2.07 and 230 μM, respectively. TX-1918 inhibits the C-terminal domain of HIV-1 CA (CA CTD)(IC50 =3.81 μM), and inhibits the viral replication (IC50 =15.16 μM)[1][2].

• Target Antigen:

  HIV; PKA; PKC; Src

• Type:

  Reference compound

• Related Pathways:

  Anti-infection;Epigenetics;Protein Tyrosine Kinase/RTK;Stem Cell/Wnt;TGF-beta/Smad

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/tx-1918.html

• Smiles:

  O=C1/C(C(C=C1)=O)=C\C2=CC(C)=C(O)C(C)=C2

• Molecular Weight:

  228.24

• References & Citations:

  [1]Hori H, et al., TX-1123: an antitumor 2-hydroxyarylidene-4-cyclopentene-1,3-dione as a protein tyrosine kinase inhibitor having low mitochondrial toxicity. Bioorg Med Chem. 2002 Oct;10(10):3257-65.|[2]Zhang DW, et al., A HTRF based competitive binding assay for screening specific inhibitors of HIV-1 capsid assembly targeting the C-Terminal domain of capsid. Antiviral Res. 2019 Sep;169:104544.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  503473-32-3